Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma

Research output: Contribution to journalArticlepeer-review

Abstract

In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.

Original languageEnglish
Pages (from-to)303-305
Number of pages3
JournalInternal Medicine
Volume42
Issue number3
DOIs
Publication statusPublished - 2003 Mar 1

Keywords

  • Angiogenic growth factors
  • Multiple myeloma
  • Thalidomide
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma'. Together they form a unique fingerprint.

Cite this